Just like our memory and reflexes, the ageing of our immune system can not only cause it to forget how to react to certain ...

and the company states that 40% of the world’s children receive a GSK vaccine each year. A key product for the company is Shingrix (recombinant zoster vaccine), which is a vaccine that protects ...

GSK says following the FDA approval ... A non-live, recombinant vaccine given intramuscularly in two doses, Zostavax (Zoster Vaccine Recombinant, Adjuvanted) is licensed for the prevention ...

GlaxoSmithKline Pharmaceuticals Limited is a subsidiary of UK-based GSK Plc ... the Company launched Shingrix, a vaccine for prevention of herpes zoster (HZ) and postherpetic neuralgia (PHN ...

Q3 results confirms that the U.S. vaccine market for respiratory syncytial virus (RSV), led by Pfizer (PFE) and GSK (GSK), is ...

Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for ...

The print ads featured a prominent display of a person’s back, highlighting where shingles rashes typically emerge.

GlaxoSmithKline (GSK) has received approval for its vaccine, AREXVY, in Canada to prevent lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in adults aged 50 to 59 ...

Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...

Jefferies lowered GSK (NYSE:GSK) to hold, citing a valuation disconnect between fundamentals and price. Jefferies said it ...

vaccine for older adults. Although vaccines constitute a substantial part of GSK’s portfolio, Walmsley emphasised that the company has more to offer than just that: “Vaccines is a big part of ...

GlaxoSmithKline (GSK) has received approval for its vaccine, AREXVY, in Canada to prevent lower respiratory tract disease ...